Suchen
Alkermes Plc
ALKSZur Watchlist hinzufügen
55.080USD
0.0000.00%
Handelsschluss 06/26, 16:00（ET）Kurse um 15 Minuten verzögert
9.09BMarktkapitalisierung
59.24KGV TTM
mehr Informationen über Alkermes Plc Unternehmen
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Alkermes Plc Informationen
BörsenkürzelALKS
Name des UnternehmensAlkermes Plc
IPO-datumJul 16, 1991
CEOPops (Richard F)
Anzahl der mitarbeiter1800
WertpapierartOrdinary Share
GeschäftsjahresendeJul 16
AddresseConnaught House
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
PostleitzahlD04 C5Y6
Telefon35317728000
Websitehttps://www.alkermes.com/
BörsenkürzelALKS
IPO-datumJul 16, 1991
CEOPops (Richard F)
Führungskräfte von Alkermes Plc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
229.52K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
77.39K
-5.17%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
25.68K
-7.79%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
18.22K
+25.61%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Mr. C. Todd Nichols
Mr. C. Todd Nichols
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
229.52K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
77.39K
-5.17%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Alkermes Plc?
Die fünf größten Anteilseigner von Alkermes Plc sind: Mr. Richard F. Pops
Wie viele Institutionen halten Anteile an Alkermes Plc (ALKS)?
Mit Stand vom 2026Q1 halten 783 Institutionen Anteile an Alkermes Plc, mit einem Gesamtmarktwert von etwa 182.39M, was 109.43% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -11997400.00 gestiegen.
Was ist die größte Einnahmequelle von Alkermes Plc?
Am 2026Q1 erzielte das Geschäft mit VIVITROL für Alkermes Plc den höchsten Umsatz in Höhe von 467.91M, was 31.70% des Gesamtumsatzes entspricht.
